Paracétamol cafeine

Phase 2Small molecule

UUniversity of Monastir

Paracétamol cafeine is one of 17 small molecule programs targeting Renal Colic. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Renal ColicRecruiting

Renal ColicPhase 2

Recruiting

Competition

Competitive Landscape

19 competitors in Renal Colic

#DrugCompanyPhaseTrials

MS Contin

HHikma Pharmaceuticals LLC

Approved

6 2

Naropin

FFresenius Kabi USA, LLC

Approved

2 3

Duragesic

CCephalon

Approved

2 4

Oruvail

WWyeth-Lederle Vaccines

Approved

2 5

Demerol

QQuagen

Approved

1 6

Suboxone

IIndivior Inc.

Approved

1 7

Celebrex

PPhiladelphia Eye Associates

Approved

1 8

Ketalar

AAultman Health Foundation

Approved

—9

Transderm Scop

BBaxter Healthcare Corporation

Voltaren

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Renal Colic1 trial

Paracetamol-Tramadol and Paracetamol-caffeine Versus Placebo in the Emergency Discharge Treatment of Renal Colic

Recruiting·UUniversity of Monastir·Phase 2·NCT06345716·1,500 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Paracétamol cafeine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Paracétamol cafeine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Paracétamol cafeine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Monastir company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Monastir

Paracétamol cafeine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Renal Colic1 trial

References

Drug Info

Quick Facts

Related News